期刊文献+

保妇康栓和干扰素栓对低度子宫颈上皮内瘤变1级作用的临床研究 被引量:11

The clinical observation for Baofukang and interferon in promoting the regression of low-grade cervical intraepithelial neoplasia
下载PDF
导出
摘要 目的比较保妇康栓和干扰素栓对低度宫颈上皮内瘤变(CIN)转归的疗效。方法选取2004年3月至2011年3月北京大学深圳医院经阴道镜下活检诊断为CIN1的高危HPV感染患者369例,分为保妇康栓组(113例)、干扰素栓组(143例)和对照组(113例),疗程3个月,治疗结束后每6~12个月监测患者的宫颈液基细胞学(LCT)和高危HPVDNA。对宫颈细胞学ASCUS及以上病变及/或高危HPV阳性者行阴道镜下多点活检,病理诊断确定转归。结果保妇康栓组、干扰素栓组和对照组治疗后6个月均未见病变进展。3组患者的病变逆转率与持续率比较,差异均无统计学意义(P〉0.05)。保妇康栓组治疗后12、24个月病变逆转率明显高于对照组(P〈0.05),病变持续率明显低于对照组(P〈0.05);干扰素栓组病变逆转率、持续率与对照组比较,差异均无统计学意义(P〉0.05);3组患者的病变进展率比较,差异无统计学意义(P〉0.05)。保妇康栓组治疗后24个月HPV转阴率高于干扰素栓组和对照组(P〈0.05)。结论保妇康栓有促进CIN1逆转和清除HPV的作用,明显提高HPV的临床转阴率。 Objective To investigate the curative effect of baofukang suppository and interferon in low- grade cervical intraepithetial neoplasia (CIN1) and to compare their effects in clearing human papilloma virus (HPV). Methods From March 2004 to March 2011, 369 cases with CIN1 and HPV infection were enrolled in this study. Patients were divided into baofukang group (group 1, 113 cases), interferon group (group 2, 143 cases) and control group (group 3, 113 cases). All patients were under follow- up for 24 months by using liquid- based cytology test combined with high- risk HPV test (HC-Ⅱ ) every 6 to 12 months. If the cervical cytology indicated as ASC- US or more severe lesion and/or HR- HPV positive, colposcopy and biopsies were performed. Results There was no progression case and the persistence and regression rate of CIN1 had no statistical difference between three groups at 6 months. At 12 months and 24 months, patients in group 1 had lower rate of persistence and high- er rate of regression than that in the other two groups, and they had statistical differences, hut not between group 2 and group 3; as for the progression rate, no statistical difference between the three groups. At 24 months, group 1 had higher clearance rate of HPV than that in the other two groups (P〈0. 05). Conclusions Baofukang supposi- tory can promote the CIN1 regression and HPV clear, and increase the rate of negative- inverted distinctly, while interferon had no such effects.
出处 《中国妇产科临床杂志》 2013年第6期509-512,共4页 Chinese Journal of Clinical Obstetrics and Gynecology
关键词 保妇康栓 干扰素栓 宫颈上皮内瘤变 人乳头瘤病毒 疾病转归 Baofukang suppository interferon suppository cervical intraepithelial neoplasia human papil- lomavirus disease outcome
  • 相关文献

参考文献15

  • 1Munoz N, Bosch FX, Castellsague X, et al. Against which hu- man papillomavirus types shall we vaccinate and screen? The in- ternational perspective Int J Cancer, 2004, 111:278 - 285.
  • 2Comeanu LM, Stnculescu D, Corneanu C. HPV and cervical squamous intraepithelial lesions: clinicopathological study. Rom J Morphol Embryol, 2011, 52.. 89-94.
  • 3Apqar BS, Kittendorf AL, Bettcher CM, et al. Update on ASCCP consensus guidelines for abnormal cervical screening tests and cervical histology. Am Faro Physician, 2009, 80.. 147 - 155.
  • 4Fontaine PL, Saslow D, King VJ. ACS/P/ASCP guide- lines for the early detection of cervical cancer. Am Fam Physi- dan, 2012, 86: 501, 506-507.
  • 5张小燕,卞美璐,房青,陈庆云,陈志华,徐梅.保妇康栓对人乳头状瘤病毒抑制作用的实验研究[J].中日友好医院学报,2007,21(4):216-219. 被引量:63
  • 6卞美璐,陈庆云,朱鹃,马莉,郝敏,刘军,陈颖.保妇康栓治疗宫颈持续人乳头瘤病毒感染炎性疾病的临床观察[J].中国实用妇科与产科杂志,2010,26(5):383-385. 被引量:54
  • 7李雨聪,王冬.重组人干扰素α2β栓治疗HPV感染临床观察[J].重庆医学,2011,40(26):2677-2678. 被引量:28
  • 8Wright TCJr, Massad LS, Dunton CJ, et al. 2006 consen- sus guidelines for the management of women with cervical in traepithelial neoplasia or adenocareinoma in situ. Am J Ob- stetGynecol, 2007, 197: 340-345.
  • 9Rouzier R. Management of CIN1. J Gyneeol Obstet Biol Re- prod, 2008, 37 114-120.
  • 10Petty KU. Management options for cervical intraepithelial neoplasia. Best Pract Res Clin Obstet Gynaecol, 2011, 25: 641 - 651.

二级参考文献57

共引文献292

同被引文献133

引证文献11

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部